Published in

Elsevier, Cancer Letters, 2(333), p. 222-228, 2013

DOI: 10.1016/j.canlet.2013.01.036

Links

Tools

Export citation

Search in Google Scholar

The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer.

Journal article published in 2013 by Miriam Lohr, Karolina Edlund, Johan Botling, Seddik Hammad, Birte Hellwig, Amnah Othman, Anders Berglund, Mats Lambe, Lars Holmberg, Simon Ekman, Michael Bergqvist, Fredrik Pontén, Cristina Cadenas, Rosemarie Marchan ORCID, Jan G. Hengstler and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

A prognostic impact of immunoglobulin kappa C (IGKC) expression has been described in cancer. We analysed the influence of B-cell and plasma cell markers, as well as IGKC expression, in non-small lung cancer (NSCLC) using immunohistochemistry on a tissue microarray. IGKC protein expression was independently associated with longer survival, with particular impact in the adenocarcinoma subgroup. Moreover, a correlation was seen with CD138+ cells, but not with CD20. CD138 expression revealed a comparable association with survival. In conclusion, IGKC expression in stroma-infiltrating plasma cells is a prognostic marker in NSCLC, supporting emerging treatment concepts that exploit the humoral immune response.